InvestorsHub Logo
Followers 468
Posts 26923
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 659

Monday, 09/23/2013 10:12:40 AM

Monday, September 23, 2013 10:12:40 AM

Post# of 724
8:26AM On The Wires (WIRES) : NuPathe (PATH) announced the co has initiated dosing of patients for NP101-015, a Phase 1 study of ZECUITY (sumatriptan iontophoretic transdermal system) in adolescents with a history of migraine attacks. This open label, single-dose study will assess the safety, pharmacokinetics, and tolerability of ZECUITY in adolescent migraine patients.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PATH News